Immuron Limited (ASX: IMC) - Share Price

Current share price for IMC : $0.047 0.001 (2.08%)⁺

Immuron Limited (IMC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian biopharmaceutical company engaged in the development and commercialization of orally delivered targeted polyclonal antibodies for the treatment of inflammation-related diseases and infectious diseases.

IMC General Information ⁺

ASX Code	IMC
Website	http://www.immuron.com.au
Industry/Sector	Biotechnology
Market Cap ($M)	15
IMC Share Price	$0.047
Day High	$0.047
Day Low	$0.047
Last Close	$0.048
IMC Share Price Movement	$0.00 ( 2.08% )

Prices as at 11:35, 21 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Immuron Limited (IMC) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Immuron Limited (IMC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Immuron Limited (IMC) price-sensitive announcements

IMC - Immuron FY26 Sales Update

Immuron Limited has announced continued sales growth for FY26, driven by the performance o

Immuron Limited (IMC)
16 Jul 2026 | 10:22 AM

IMC - Response to ASX Price Query

Immuron Limited (IMC) responded to a price query from the ASX, confirming that they are un

Immuron Limited (IMC)
28 May 2026 | 12:57 PM

IMC - Immuron Double Digit 3Q Sales Growth

Immuron Limited, an Australian biopharmaceutical company, reported a 16% increase in globa

Immuron Limited (IMC)
17 Apr 2026 | 9:30 AM

IMC - Strategic Update and HY26 Results

Immuron Limited, a commercial-stage biopharmaceutical company, reported its HY26 results a

Immuron Limited (IMC)
25 Feb 2026 | 4:42 PM

Immuron Limited (IMC) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Immuron Limited (IMC) ORDINARY FULLY PAID	Health Care	$15	PROIBS US Distribution Agreement	4 Sep 2026 9:24AM	$0.037	$0.047	risen by 27.03%
Immuron Limited (IMC) ORDINARY FULLY PAID	Health Care	$15	FY26 Results Presentation	28 Aug 2026 8:39AM	$0.037	$0.047	risen by 27.03%
Immuron Limited (IMC) ORDINARY FULLY PAID	Health Care	$15	Appendix 4E Preliminary Final Report	28 Aug 2026 8:37AM	$0.037	$0.047	risen by 27.03%
Immuron Limited (IMC) ORDINARY FULLY PAID	Health Care	$15	Emerging Growth Conference Presentation	19 Aug 2026 9:34AM	$0.039	$0.047	risen by 20.51%
Immuron Limited (IMC) ORDINARY FULLY PAID	Health Care	$15	Emerging Growth Conference	13 Aug 2026 8:49AM	$0.037	$0.047	risen by 27.03%
Immuron Limited (IMC) ORDINARY FULLY PAID	Health Care	$15	Investor Presentation	27 Jul 2026 9:09AM	$0.038	$0.047	risen by 23.68%

IMC Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$3.84	-$1.30	-42.90%	0.00%	0.0%
2025A	-$5.22	-$2.30	-10.70%	0.00%	0.0%
2024A	-$5.77	-$2.50	52.40%	0.00%	0.0%

IMC Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
CSL Limited (CSL)	$85,208M	0.7309	-0.4447	0.0545	11.0002	19.8081	18.7837	2.39%	2.34%	2.42%
Clinuvel Pharmaceuticals Limited (CUV)	$411M	-0.0696	-0.0719	0.0242	12.2156	13.1613	12.8504	0.61%	0.61%	0.61%
Immuron Limited (IMC)	$15M	-0.4292	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,675M	-0.4380	0.0000	0.0000	0.0000	0.0000	326.9841	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,931M	-1.3893	0.0000	-0.8998	0.0000	186.0341	1,856.3830	0.00%	0.00%	0.00%

IMC Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	1.41	0.00
Market	0.33	13.70	1.17	0.80
Sector	0.67	37.30	2.73	3.16

IMC Directors

Name	Position	Start Date
Mr Daniel Pollock	Non-Executive Director	11 Oct 2012
Mr Ravi Savarirayan	Non-Executive Director	7 Apr 2017
Dr Jeannie(Jeannette) Joughin	Non-Executive Director	1 Jun 2024
Mr Paul Brennan	Non-Executive Director, Non-Executive Chairman	16 Mar 2022

Immuron Limited (IMC) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
12 Mar 2024	POLLOCK, Daniel	Buy	Direct Shares	200,000	$0.120	$24,000.000
12 Mar 2024	POLLOCK, Daniel	Exercise	Options	200,000	$0.120	$24,000.000
8 Mar 2024	POLLOCK, Daniel	Sell	Direct Shares	200,000	$0.157	$31,400.000

See all changes in directors' interest & trades for Immuron Limited (IMC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMC Management

Name	Position
Jerry Kanellos	Chief Scientific Officer
Flavio Palumbo	Chief Commercial Officer
Steven Lydeamore	Chief Executive Officer
Olga Smejkalova	Company Secretary

IMC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Immuron Limited (IMC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
113,417,824 (42.29%)	HSBC Custody Nominees (Australia) Limited

IMC Calendar of Events

Date	Event
27 August 2027	Report (Prelim)
24 February 2027	Report (Interim)
24 September 2026	Report (Annual)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us